Biotech Values

[Biowatch]

Re: GTCB’s nuclear-transfer IP

Do you know how often GTCB uses nuclear transfer versus microinjection? The latter is now almost "old fashioned" in the scheme of things biotech, but has been used successfully for a long time. Also, would they have to pay royalties to anyone when they use microinjection?

And of course, try to find out how much they have to pay in royalties. (e.g., what percent)

>> [This USPTO decision affects GTCB indirectly because GTCB licensed its nuclear-transfer technology from Advanced Cell Technology (ACT). Thus, GTCB may now owe license fees/royalties to GERN instead of to ACT.

Importantly, the USPTO action does not affect GTCB’s lead, drug, ATryn, because the goat herd for ATryn was created using microinjection rather than nuclear transfer.] <<